Why Moderna Stock Zoomed Higher on Wednesday
Moderna (NASDAQ: MRNA) closed nearly 6.5% higher on Wednesday thanks to the results of an early-stage clinical study of its coronavirus candidate on older patients.
In the study, mRNA-1273 was found to produce the neutralizing antibodies that should immunize the body against the coronavirus. It also did so at levels comparable to those of younger patients who have received the vaccine, and without serious adverse effects.
News of mRNA-1273 has been consistently positive, with all clinical research so far indicating that it is efficacious. It's particularly encouraging that this seems to apply to older patients too, as they are considered to be especially vulnerable to the coronavirus, and more broadly because vaccines in general tend to be less effective in older people.
Source Fool.com
